Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Operations (2016 - 2025)

Iradimed (IRMD) has disclosed Cash from Operations for 13 consecutive years, with 6986075.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 23.36% to 6986075.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 25011497.0, a 6.21% increase, with the full-year FY2024 number at 25624463.0, up 90.3% from a year prior.
  • Cash from Operations was 6986075.0 for Q3 2025 at Iradimed, down from 7746261.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9115714.0 in Q3 2024 to a low of 943081.0 in Q1 2021.
  • A 5-year average of 4179724.74 and a median of 3883154.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 64.64% in 2023, then surged 554.54% in 2024.
  • Iradimed's Cash from Operations stood at 3366043.0 in 2021, then decreased by 9.72% to 3038844.0 in 2022, then grew by 28.75% to 3912480.0 in 2023, then skyrocketed by 53.02% to 5987069.0 in 2024, then increased by 16.69% to 6986075.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Cash from Operations are 6986075.0 (Q3 2025), 7746261.0 (Q2 2025), and 4292092.0 (Q1 2025).